Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

China Resources Sanjiu Medical & Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results

Aug 26

Does China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Have A Healthy Balance Sheet?

Aug 09

Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings

Jul 12

China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Is Increasing Its Dividend To CN¥1.50

Jun 09

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 23

An Intrinsic Calculation For China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Suggests It's 50% Undervalued

Apr 16

Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings

Mar 20

Do China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Earnings Warrant Your Attention?

Feb 28

CEO

China Resources Sanjiu Medical & Pharmaceutical CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hui Zhou	VP, Secretary	19.5yrs	CN¥3.10m	0.013% CN¥ 8.1m
Huawei Qiu	Chairman	7.1yrs	CN¥4.61m	0.019% CN¥ 11.8m
Fang Xu	Independent Director	6.5yrs	CN¥150.00k	Veri yok
Xingtian Yao	Independent Director	6.5yrs	CN¥150.00k	Veri yok
Ran Tao	Chairman of the Supervisory Board	5.9yrs	Veri yok	Veri yok
Na Tang	Non-Employee Supervisor	5.3yrs	Veri yok	Veri yok
Qiang Zhang	Independent Director	1.1yrs	Veri yok	Veri yok
Xiaosong Bai	Non-Independent Director	2.6yrs	Veri yok	Veri yok
Xingpin Cui	Non-Independent Director	2.6yrs	Veri yok	Veri yok
Yang Don	Director	2.9yrs	CN¥150.00k	Veri yok
Jihong Zhang	Supervisor	6.5yrs	Veri yok	Veri yok
Shutian Yu	Director	2yrs	Veri yok	Veri yok

5.6yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 000999 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

China Resources Sanjiu Medical & Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

High number of new directors

High number of new directors

Recent updates

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 25%

Investor sentiment deteriorates as stock falls 17%

Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Does China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Have A Healthy Balance Sheet?

Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Investor sentiment deteriorates as stock falls 27%

China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Is Increasing Its Dividend To CN¥1.50

Dividend increased to CN¥1.50

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

High number of new directors

An Intrinsic Calculation For China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Suggests It's 50% Undervalued

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings

Do China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Earnings Warrant Your Attention?

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 15 June 2023

Now 22% undervalued

Full year 2022 earnings released: EPS: CN¥2.48 (vs CN¥2.09 in FY 2021)

Full year 2022 earnings released: EPS: CN¥2.48 (vs CN¥2.09 in FY 2021)

Now 20% undervalued

Price target increased by 7.3% to CN¥63.23

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2022

Price target increased to CN¥61.88

High number of new directors

Price target increased to CN¥55.96

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS misses analyst expectations

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 12 August 2022

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) agreed to acquire 28% stake in KPC Pharmaceuticals, Inc. (SHSE:600422) from Holley Pharmaceutical Group Co., Ltd and Holley Group Company Limited for CNY 2.9 billion.

High number of new directors

High number of new directors

Price target increased to CN¥45.76

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Proposes Cash Dividend as of 31 December 2021

Investor sentiment improved over the past week

Price target increased to CN¥41.03

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Board Elections

Price target increased to CN¥38.36

High number of new directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.51 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.73 (vs CN¥0.54 in 2Q 2020)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.66 (vs CN¥0.54 in 1Q 2020)

Consensus EPS estimates fall to CN¥1.83

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year December 31, 2020

Full year 2020 earnings released: EPS CN¥1.63 (vs CN¥2.16 in FY 2019)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥24.96

Third quarter earnings released

Third-quarter earnings released: Earnings beat expectations, revenue disappoints

New 90-day low: CN¥26.02

New 90-day low - CN¥27.00

First half earnings released

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş